Table IV.
Protection of INH against development of active TB in HIV infected individuals who were TST positive or TST Negative (from placebo controlled trials)
| Studies | Year | Country | Risk reduction compared to placebo |
|
| Among TST positive persons % (range) | Among TST negative persons | |||
| Pape et al59 | 1993 | Haiti | 76 (0-94) | 30 (0-85) |
| Whalen et al60 | 1997 | Uganda | 70 (32-87) | 26 (0-70) |
| Hawken et al61 | 1997 | Kenya | 40 (0 - 77) | 0 (0 - 45) |
| Mwinga et al62 | 1998 | Zambia | 72 (0-93) | 18 (0 - 70) |
| Pooled65 | 2010 | All | 60 (35-76) | 16 (0 - 40) |
| Samandari et al38 | 2009 | Botswana** | 90 (N/A) | 14 (N/A) |
* Pooled risk reduction from systematic review and meta-analysis of the above 4 studies plus Gordin et al63 and Garcia et al64
**
The Botswana trial compared rate of reduction with 36 months INH vs. 6 months INH in HIV infected persons who were initially TST positive or TST negative, Hence the placebo control was given from month 7 to 36; both groups received INH for the first 6 months. Superscript numerals denote reference numbers